[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355349-105":59,"doc-detail-355349-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-application-of-experimental-models-for-the-drug-discovery-for-digestive-tumors","The application of experimental models for the drug discovery for digestive tumors","","Drug development for digestive tumors depends on various preclinical models to evaluate their efficacy and safety. Traditional 2D cell lines and animal models do not fully reproduce human pathology, while newer systems such as 3D organoids, tumor spheroids, and organ-on-a-chip platforms can better reflect tissue architecture and microenvironment. Patient-derived xenografts and genetically engineered models preserve genetic heterogeneity and immune context, supporting assessment of drug efficacy and resistance mechanisms. The review compares strengths and limits across model types and outlines uses in target discovery, screening, and mechanistic profiling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-application-of-experimental-models-for-the-drug-discovery-for-digestive-tumors/355349/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-application-of-experimental-models-for-the-drug-discovery-for-digestive-tumors/355349.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are preclinical models critical in digestive tumor drug development?","Question",{"text":112,"@type":113},"They are used to evaluate drug efficacy and safety before clinical trials. The goal is to predict performance in humans and reduce clinical failure rates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations do traditional preclinical models have for digestive tumors?",{"text":117,"@type":113},"Common approaches such as 2D cell lines and conventional animal models fail to recapitulate complex human pathology and the relevant microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"Which newer model systems are highlighted as improving translational relevance?",{"text":121,"@type":113},"The review emphasizes 3D organoids, tumor spheroids, and organ-on-a-chip systems, which can better mimic tissue architecture and microenvironment. It also notes patient-derived xenografts and genetically engineered models for preserving genetic heterogeneity and immune context.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355349,1790322800,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Zheng et al. Molecular Cancer (2026) 25:84 Molecular Cancer  \n[https://doi.org/10.1186/s12943-025-02558-6](https://doi.org/10.1186/s12943-025-02558-6)  \nREVIEW Open Access  \nThe application of experimental models for the drug discovery for digestive tumors  \nLinxiao Zheng1†, Wen Shuai1†, Yinyang Liu1†, Yang Deng1, Ji Bao1*, Xiuying Hu1* and Guan Wang1*  \nAbstract  \nDrug development for digestive tumors depends on various preclinical models to evaluate their efficacy and safety. Traditional models, such as 2D cell lines and animal models, fail to recapitulate the complex pathology in the human body. Recently, novel models, such as 3D organoids, tumor spheroids, and organ-on-a-chip systems, have undergone rapid growth. These models can recapitulate tissue architecture and the microenvironment in amore faithful way, enhancing the translational relevance of in vitro experiments to clinical outcomes. Moreover, patient-derived xenografts and genetically engineered models retain the genetic heterogeneity and immune contexture of original tumors, which play critical roles in assessing drug efficacy and resistance mechanisms. This review aims to explore the strengths and limitations of diverse models in drug discovery for digestive tumors. In addition, we delineate their utility in target discovery or validation, lead compound screening, and preclinical mechanistic profiling. Current studies indicate that drug failure rates can be minimized by the integration of 2D high-throughput screening, 3D organoid/tumor spheroid screening, and in vivo animal validation. Multimodal synergy and personalized models can lead to the development of more efficient and precise approaches for treating digestive tumors.  \nKeywords Digestive tumors, Drug development, Preclinical models, Organoids, Organ-on-a-Chip, Genetically engineered animals  \n†Linxiao Zheng, Wen Shuai andYinyang Liu contributed equally to this work.  \n*Correspondence: Ji Bao [baoji@scu.edu.cn](baoji@scu.edu.cn)[ ](baoji@scu.edu.cn)Xiuying Hu [huxiuying@scu.edu.cn](huxiuying@scu.edu.cn)[ ](huxiuying@scu.edu.cn)Guan Wang [guan8079@163.com](guan8079@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZheng et al. Molecular Cancer (2026) 25:84 Page 2 of 39  \nGraphical abstract  \nCreated in [https://BioRender.com](https://BioRender.com).  \nIntroduction  \nDigestive tumors, including colorectal cancer, gastric cancer, and other digestive cancers, pose a significant burden worldwide. For example, colorectal cancer (CRC) accounts for approximately 10% of new cancer cases worldwide, making it the second leading cause of cancer death. Similarly, gastric cancer ranks fifth among the most commonly diagnosed cancers and the fourth leading cause of cancer mortality [1]. Given this burden, intercepting carcinogenesis at its earliest stages is esse","cbCaiiruwShu36gn","https://ap.wps.com/l/cbCaiiruwShu36gn","pdf",6023874,39,"English","# Introduction\n## Preclinical phases in digestive tumor drug development\n# Abstract\n## Strengths and limitations of model types\n# Keywords","[{\"question\":\"Why are preclinical models critical in digestive tumor drug development?\",\"answer\":\"They are used to evaluate drug efficacy and safety before clinical trials. The goal is to predict performance in humans and reduce clinical failure rates.\"},{\"question\":\"What limitations do traditional preclinical models have for digestive tumors?\",\"answer\":\"Common approaches such as 2D cell lines and conventional animal models fail to recapitulate complex human pathology and the relevant microenvironment.\"},{\"question\":\"Which newer model systems are highlighted as improving translational relevance?\",\"answer\":\"The review emphasizes 3D organoids, tumor spheroids, and organ-on-a-chip systems, which can better mimic tissue architecture and microenvironment. It also notes patient-derived xenografts and genetically engineered models for preserving genetic heterogeneity and immune context.\"}]","The application of experimental models for the drug discovery for digestive tumors | PDF",1790117966,98,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/280e95a19b8cf4aaee0555aaf193b539.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94fed1a8445782a5d065c204c2fdef3d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bb3e4304b7c512a848b75534c80e474.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb7f69f77519855d9855e3b71d511573.webp",980,1306]